newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule - Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88% - Clinical validation further demonstrates